The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Prognostic Genes of Breast Cancer Identified by Gene Co-expression Network Analysis
Open accessAbstract
Abstract Background Breast cancer is the mostly diagnosed malignance in female worldwide. However, the mechanisms of its pathogenesis remain largely unknown. Methods In this study, we used weighted gene co-expression network analysis (WGCNA) to identify novel biomarkers associated with the prognosis of breast cancer. Gene expression profiles were obtained from the Gene Expression Omnibus (GEO) database. Results A total of 5 modules were identified via the average linkage hierarchical clustering. And a module significantly with the pathological grade was screened out. 33 genes with high connectivity in the clinically significant module were identified as hub genes. Among them, CASC5 and RAD51 were negatively associated with the overall survival and disease-specific survival. Similar results were observed in the validation dataset. Protein levels of CACS5 and RAD51 were also significantly higher in tumor tissues compared with normal tissues based on the analysis of the Human Protein Atlas. Convincingly, qRT-PCR analysis of breast cancer tissues and matched paracancerous tissue demonstrated that CACS5 and RAD51 were significantly upregulated in in breast cancer compared to paracancerous tissues. Further cell proliferation assay indicated that CACS5 and RAD51 depletion decreased cell proliferation capability. Conclusion In conclusion, our findings suggested that CASC5 and RAD51 could serve as biomarkers related to the prognosis of breast cancer and may be helpful for revealing pathogenic mechanism and developing further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis
Clarke, C., Madden, S. F., Doolan, P., Aherne, S. T., Joyce, H., O’Driscoll, L., Gallagher, W. M., Hennessy, B. T., Moriarty, M., Crown, J., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt208 · Cited by 849
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208561 · Cited by 785
Lánczky, A., Nagy, Á., Bottai, G., Munkácsy, G., Szabó, A., Santarpia, L., & Győrffy, B. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4013-7 · Cited by 768
Breast cancer as a systemic disease: a view of metastasis
Redig, A. J., & McAllister, S. S. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12084 · Cited by 709
Choosing between glycolysis and oxidative phosphorylation: a tumor’s dilemma?
Jose, C., Bellance, N., & Rossignol, R. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.10.012 · Cited by 518
Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin
McAllister, S. S., Gifford, A. M., Greiner, A. L., Kelleher, S. P., Saelzler, M. P., Ince, T. A., Reinhardt, F., Harris, L. N., Hylander, B. L., Repasky, E. A., et al. (2008) · Cell · doi:10.1016/j.cell.2008.04.045 · Cited by 431
Shubbar, E., Kovács, A., Hajizadeh, S., Parris, T. Z., Nemes, S., Gunnarsdóttir, K., Einbeigi, Z., Karlsson, P., & Helou, K. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-1 · Cited by 373
HER2 in Breast Cancer: A Review and Update
Krishnamurti, U., & Silverman, J. F. (2014) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000015 · Cited by 328
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V, Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1122 · Cited by 307
Zou, J. X., Duan, Z., Wang, J., Sokolov, A., Xu, J., Chen, C. Z., Li, J. J., & Chen, H.-W. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0459 · Cited by 201
In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis
Vaidyanathan, S., Cato, K., Tang, L., Pavey, S. J., Haass, N. K., Gabrielli, B. G., & Duijf, P. H. G. (2016) · Oncogene · doi:10.1038/onc.2016.94 · Cited by 81
Gütgemann, I., Lehman, N. L., Jackson, P. K., & Longacre, T. A. (2008) · Modern Pathology · doi:10.1038/modpathol.3801022 · Cited by 68
Huang, Y., Wang, H., Lian, Y., Wu, X., Zhou, L., Wang, J., Deng, M., & Huang, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0114-4 · Cited by 63
Prognostic genes of breast cancer revealed by gene co-expression network analysis
Shi, H., Zhang, L., Qu, Y., Hou, L., Wang, L., & Zheng, M. (2017) · Oncology Letters · doi:10.3892/ol.2017.6779 · Cited by 48
Pan, H., Su, H., Hsu, C., Huang, G.-J., & Wu, T. T.-L. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s136491 · Cited by 44
Meng, L., Xu, Y., Xu, C., & Zhang, W. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s113855 · Cited by 37
Enhanced expression of KIF4A in colorectal cancer is associated with lymph node metastasis
Matsumoto, Y., Saito, M., Saito, K., Kanke, Y., Watanabe, Y., Onozawa, H., Hayase, S., Sakamoto, W., Ishigame, T., Momma, T., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.7555 · Cited by 29
Izumi, M., Mizuno, T., Yanagi, K., Sugimura, K., Okumura, K., Imamoto, N., Abe, T., & Hanaoka, F. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.779371 · Cited by 23
Guan, C., Zhang, J., Zhang, J., Shi, H. M., & Ni, R. (2016) · Oncology Letters · doi:10.3892/ol.2016.4611 · Cited by 14
Huang, C., Li, F. X., Pan, S., Xu, C., Dai, J. Q., & Zhao, X. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7488 · Cited by 12
Weitzel, J. N. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2015.06.011 · Cited by 6
Cited by
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma
Zheng, W., Lin, Q., Issah, M. A., Liao, Z., & Shen, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08660-4 · Cited by 21
Cai, X., Zheng, X., Wang, Y., Tian, L., & Mao, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.843807 · Cited by 6
Metadata
- Authors
- Tang, J., Kong, D., Cui, Q., Wang, K., Zhang, D., Gong, Y., & Wu, G.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2018-09-11
- Volume
- 8
- Pages
- 374-374
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3147586197
- Cited by
- 262
- References
- 29
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.